Senate Democrats Soften, But Don’t Yank, COVID Relief Bill’s Medicaid Rebate Language

In a concession to drug companies, Senate Democrats reportedly have agreed to delay by one year—from Jan. 1, 2023 to Jan. 1, 2024—the effective date of language in the $1.9 trillion COVID-19 relief bill that might lead to 340B ceiling

Read More »

340B Report Publisher/CEO: Look for a Return to an Era of 340B Guidance

Recent developments in federal court bode well for 340B providers trying to restore access to 340B pricing in the contract pharmacy setting, 340B Report Publisher and CEO Ted Slafsky’s take in his latest column for the Omnicell blog

The Biden administration’s embrace of the federal government’s traditional stance on the enforceability of program guidance—which the Trump administration rejected—may lead to stronger enforcement of 340B program guidance and possibly even the issuance of new 340B guidelines, 340B Report Publisher

Read More »

DOJ Opposes Sanofi’s Move to Head Off 340B Dispute Resolution in Contract Pharmacy Battle

The U.S. Justice Department (DOJ) has slammed a second drug manufacturer’s motion before a federal court to block implementation of the 340B program’s new administrative dispute resolution (ADR) process.

First, on Feb. 16 in a federal district court in

Read More »

340B Providers Cheer Bipartisan House Letter to HHS on Manufacturer Actions

Safety-net hospitals, health centers, and HIV/AIDS clinics yesterday applauded the 226 U.S. representatives—more than half of the House’s members—who signed Friday’s bipartisan letter to U.S. Health and Human Services (HHS) Acting Secretary Norris Cochran seeking “immediate action to ensure that

Read More »

N.Y. and Calif. 340B Pharmacies Get Reprieve From Medicaid Cuts

New York State and California’s nationally watched efforts to transfer their pharmacy programs for low-income individuals from Medicaid managed care to Medicaid fee for service (FFS)—both scheduled to take effect on April 1—have been temporarily placed on hold. The states

Read More »

Huge COVID Relief Bill That Would Lift Medicaid Rebate Caps Moves to Senate

The U.S. House on Saturday passed a $1.9 trillion COVID-19 relief bill with language that might lead to 340B ceiling prices on some branded drugs being set lower than the drugs’ average manufacturer price (AMP).

The bill, H.R. 1319,

Read More »

226 Bipartisan U.S. House Members Ask HHS to Stop Pharma From Unilaterally Changing 340B

Slightly more than half of all U.S. Representatives signed the Feb. 26 letter to HHS urging immediate action to stop drug manufacturers from making unilateral changes to 340B | Shutterstock

Two hundred and twenty six U.S. House members—173 Democrats and 57 Republicans—have signed a letter to U.S. Health and Human Services (HHS) Acting Secretary Norris Cochran asking him “to take immediate action to ensure that manufacturers are prohibited from imposing

Read More »

Express Scripts’ New 340B Rules Will Have Big Impact on Contract Pharmacy and Drug Reimbursement, Providers and Consultants Say

340B covered entities fault Express Scripts for not communicating with them more effectively about changes in its 340B claims identification and reporting requirements, which the entities consider to be major.

340B covered entities say they are deeply concerned about pharmacy benefit manager Express Scripts’ (ESI) requirements, effective Monday, governing what pharmacies in the PBM’s network must do when they identify that a previously submitted claim is 340B-eligible. Last night, ESI told

Read More »

Bipartisan U.S. House Members Corralling Last-Minute Signatures on 340B Letter to HHS

Rep. Abigail D. Spanberger (D-Va.) is one of six U.S. House members urging colleagues to sign a bipartisan letter to HHS leadership on 340B. | C-SPAN

Today is the deadline for U.S. House members to sign a bipartisan letter asking U.S. Health and Human Services Department (HHS) leaders to act against drug manufacturers denying 340B pricing on drugs, to halt attempts to turn 340B into a

Read More »

Becerra Reconfirms Strong Support for 340B During Finance Committee Hearing

HHS Secretary-designate Xavier Becerra said he "absolutely" would commit himself to ensuring the 340B program's strength, in response to a question from Sen. John Thune (R-S.D.) | C-SPAN

Xavier Becerra, President Biden’s pick to be the next U.S. Health and Human Services (HHS) Secretary survived his U.S. Senate Finance Committee confirmation hearing yesterday, with a GOP foe of his nomination grudgingly predicting the panel would vote to confirm

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live